The Food and Drug Administration says it will begin offering faster reviews to new medicines that align with Trump ...

Paul Offit knows vaccines. A trained doctor, he spent 26 years working in pediatric infectious disease and studying the ...

Merck’s MRK second-largest product is Gardasil, which is a vaccine for the prevention of certain cancers caused by human ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed ...

Through Friday, Capital One’s COF stock had returned 10.9% for 2025, while Discover shares had returned 16% as investors became more confident the deal would be completed. The KBW Bank Index had ...

Covid vaccine sales totaled $1.8 billion for the third quarter. That blew past analysts’ estimates of $1.2 billion, and was slightly higher than a year earlier. Moderna's stock rose nearly 1.5% ...

Moderna said the FDA approved its new COVID-19 vaccine "for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor." Shares of the ...

In other words, the U.S. coronavirus vaccine market just became smaller ... It's not time to give up on the stock just yet, even with the recent regulatory changes in the U.S. Pfizer could ...

READ ALSO: 10 AI Stocks on Wall Street’s Radar and 12 AI Stocks on Latest News and Ratings. The company has acknowledged that the AI model was capable of “extreme actions” if it thought ...